UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 298

Sortiert nach

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

The Journal of cell biology, 2008-10, Vol.183 (1), p.101-116

2008

Link zum Volltext

Verfügbarkeit prüfen

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer

Molecular cancer therapeutics, 2003-05, Vol.2 (5), p.471-478

2003

Link zum Volltext

Verfügbarkeit prüfen

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

Clinical cancer research, 2009-06, Vol.15 (12), p.4147-4156

2009

Link zum Volltext

Verfügbarkeit prüfen

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.999-1006

2006

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Selective 4‑Amino-pyridopyrimidine Inhibitors of MAP4K4 Using Fragment-Based Lead Identification and Optimization

Journal of medicinal chemistry, 2014-04, Vol.57 (8), p.3484-3493

2014

Link zum Volltext

Verfügbarkeit prüfen

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

Molecular cancer therapeutics, 2003-10, Vol.2 (10), p.1011-1021

2003

Link zum Volltext

Verfügbarkeit prüfen

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Clinical & experimental metastasis, 2003-01, Vol.20 (8), p.757-766

2003

Link zum Volltext

Verfügbarkeit prüfen

Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors

Bioorganic & medicinal chemistry letters, 2010-12, Vol.20 (23), p.7037-7041

2010

Link zum Volltext

Verfügbarkeit prüfen

GDC-0449—A potent inhibitor of the hedgehog pathway

Bioorganic & medicinal chemistry letters, 2009-10, Vol.19 (19), p.5576-5581

2009

Link zum Volltext

Verfügbarkeit prüfen

Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat

Drug metabolism letters, 2016-06, Vol.10 (2), p.91

2016

Link zum Volltext

Verfügbarkeit prüfen

Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window

Journal of medicinal chemistry, 2016-06, Vol.59 (11), p.5520-5541

2016

Link zum Volltext

Verfügbarkeit prüfen

pHUSH: a single vector system for conditional gene expression

BMC biotechnology, 2007-09, Vol.7 (1), p.61-61, Article 61

2007

Link zum Volltext

Verfügbarkeit prüfen

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Blood, 2003-05, Vol.101 (9), p.3597-3605

2003

Link zum Volltext

Verfügbarkeit prüfen

Design of Selective PAK1 Inhibitor G‑5555: Improving Properties by Employing an Unorthodox Low‑pK a Polar Moiety

ACS medicinal chemistry letters, 2015-12, Vol.6 (12), p.1241-1246

2015

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors

Bioorganic & medicinal chemistry letters, 2016-08, Vol.26 (15), p.3518-3524

2016

Link zum Volltext

Verfügbarkeit prüfen

Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors

Bioorganic & medicinal chemistry letters, 2014-09, Vol.24 (18), p.4546-4552

2014

Link zum Volltext

Verfügbarkeit prüfen

Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis

ACS medicinal chemistry letters, 2015-08, Vol.6 (8), p.913-918

2015

Link zum Volltext

Verfügbarkeit prüfen

Rare neurological diseases: a practical approach to management

Practical Neurology, 2013-08, Vol.13 (4), p.219-227

2013

Link zum Volltext

Verfügbarkeit prüfen

Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series

ACS medicinal chemistry letters, 2015-06, Vol.6 (6), p.711-715

2015

Link zum Volltext

Verfügbarkeit prüfen

Regulation of ERK3/MAPK6 expression by BRAF

International journal of oncology, 2006-10, Vol.29 (4), p.839-849

2006

Link zum Volltext

Verfügbarkeit prüfen

CD109 is expressed on a subpopulation of CD34 + cells enriched in hematopoietic stem and progenitor cells

Experimental hematology, 1999-08, Vol.27 (8), p.1282-1294

1999

Link zum Volltext

Verfügbarkeit prüfen

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety

ACS medicinal chemistry letters, 2015-10, Vol.6 (12), p.1241-1246

2015

Link zum Volltext

Verfügbarkeit prüfen

CD34 + cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1 + subset following cell division ex vivo

Experimental hematology, 1999-06, Vol.27 (6), p.994-1003

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 298

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(260)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models

Discovery of Selective 4‑Amino-pyridopyrimidine Inhibitors of MAP4K4 Using Fragment-Based Lead Identification and Optimization

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors

GDC-0449—A potent inhibitor of the hedgehog pathway

Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat

Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window

pHUSH: a single vector system for conditional gene expression

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship

Discovery of a Potent (4R,5S)‑4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Design of Selective PAK1 Inhibitor G‑5555: Improving Properties by Employing an Unorthodox Low‑pK a Polar Moiety

Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors

Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors

Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis

Rare neurological diseases: a practical approach to management

Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series

Regulation of ERK3/MAPK6 expression by BRAF

CD109 is expressed on a subpopulation of CD34 + cells enriched in hematopoietic stem and progenitor cells

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety

CD34 + cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1 + subset following cell division ex vivo

Suchergebnisse filtern